Outcome | Studies | Patients (n) | Effect estimate |
---|---|---|---|
Mortality, overall RR | 10 | 847 | 0.89 (0.59, 1.33) |
   ICU patients | 7 | 547 | 0.94 (0.61, 1.45) |
   Non-ICU patients | 3 | 300 | 0.58 (0.18, 1.84) |
Infection rate, overall RR | 11 | 919 | 0.61 (0.45, 0.84)* |
   ICU patients | 5 | 524 | 0.71 (0.45, 1.12) |
   Non-ICU patients | 6 | 395 | 0.53 (0.34, 0.82)* |
Hospital LOS, overall MD | 15 | 1169 | -3.29 (-5.13, -1.45)* |
   ICU patients | 8 | 615 | -5.17 (-8.35, -1.99)* |
   Non-ICU patients | 7 | 554 | -1.86 (-3.13, -0.59)* |
ICU LOS, MD | 8 | 615 | -1.92 (-3.27, -0.58)* |
CRP, overall MD | 7 | 432 | -11.28 (-24.71, 2.16) |
   ICU patients | 6 | 405 | -9.76 (-23.57, 4.04) |
   Non-ICU patients | 1 | 27 | -46.00 (-108.12, 16.12) |
IL-6 change, MD | 3 | 105 | 37.70 (20.23, 55.16)* |
Oxygenation index, MD | 2 | 61 | 50.04 (10.99, 89.09)* |
Serum lactate, MD | 2 | 47 | -0.29 (-1.38, 0.80) |
LTB5, overall SMD | 5 | 183 | 2.86 (1.22, 4.50)* |
   ICU patients | 3 | 120 | 3.35 (0.54, 6.16)* |
   Non-ICU patients | 2 | 63 | 2.14 (0.42, 3.85)* |
LTB4, overall SMD | 6 | 188 | -0.47 (-1.18, 0.23) |
   ICU patients | 4 | 125 | -0.85 (-1.42, -0.27)* |
   Non-ICU patients | 2 | 63 | 0.34 (-1.25, 1.92) |
LTB ratio, overall MD | 4 | 163 | 0.07 (0.05, 0.09)* |
   ICU patients | 2 | 100 | 0.11 (0.01, 0.22)* |
   Non-ICU patients | 2 | 63 | 0.06 (0.05, 0.07)* |
EPA, overall SMD | 9 | 271 | 4.12 (2.99, 5.25)* |
   ICU patients | 6 | 165 | 4.65 (2.70, 6.60)* |
   Non-ICU patients | 3 | 106 | 3.64 (2.65, 4.64)* |
DHA, overall SMD | 7 | 171 | 1.84 (0.65, 3.03)* |
   ICU patients | 4 | 65 | 2.82 (0.17, 5.46)* |
   Non-ICU patients | 3 | 106 | 1.33 (-0.11, 2.78) |
Arachidonic acid, overall SMD | 6 | 171 | 0.22 (-0.20, 0.64) |
   ICU patients | 3 | 65 | 0.35 (-0.14, 0.84) |
   Non-ICU patients | 3 | 106 | 0.14 (-0.62, 0.900 |
Alpha-tocopherol, overall MD | 5 | 170 | 12.33 (8.73, 15.93)* |
   ICU patients | 3 | 104 | 10.08 (5.39, 14.76)* |
   Non-ICU patients | 2 | 66 | 15.25 (14.15, 16.35)* |
Prothromin time (Quick), MD | 2 | 300 | 0.43 (-2.62, 3.47) |
Partial thromboplastin time, MD | 2 | 65 | 10.71 (-30.08, 51.51) |
Transfused blood units, SMD | 2 | 209 | -0.05 (-0.32, 0.22) |
Platelet count | 4 | 160 | -6.32 (-31.40, 18.77) |
Triglyceride level, overall MD | 5 | 567 | 10.40 (-13.53, 34.34) |
   ICU patients | 4 | 368 | 14.16 (-13.12, 41.44) |
   Non-ICU patients | 1 | 199 | -0.89 (-23.26, 21.48) |
Serum creatinine, SMD | 3 | 309 | -3.01 (-7.11, 1.08) |
Serum urea, SMD | 2 | 53 | -0.11 (-0.30, 0.08) |
AST, overall MD | 7 | 656 | -10.05 (-18.81, -1.29)* |
   ICU patients | 4 | 373 | -10.11 (-27.31, 7.10) |
   Non-ICU patients | 3 | 283 | -8.37 (-17.36, 0.61)* |
ALT, overall MD | 7 | 482 | -9.85 (-17.49, -2.21)* |
   ICU patients | 3 | 109 | -18.18 (-21.68, -14.68)* |
   Non-ICU patients | 4 | 373 | -4.97 (-9.62, -0.32)* |
Serum bilirubin, overall MD | 4 | 520 | 0.03 (-0.33, 0.40) |
   ICU patients | 3 | 321 | 0.12 (-0.42, 0.65) |
   Non-ICU patients | 1 | 199 | -0.02 (-0.17, 0.13) |